Epidermolysis Bullosa: New Therapies Bring Hope, Healing
Recent FDA approvals have transformed the treatment approach for epidermolysis bullosa (EB), shifting from supportive care to targeted therapies. New treatments like B-VEC and pz-cel focus on correcting genetic defects and enhancing wound healing. Pediatric dermatologists emphasize the importance of proper application techniques and overall patient health to maximize treatment efficacy.
- ▪B-VEC was approved by the FDA in 2023 for recessive and dominant dystrophic EB, with expanded approval for newborns in 2025.
- ▪Pz-cel received FDA approval in April 2025 and requires careful patient management during treatment.
- ▪A topical gel containing birch bark triterpenes was approved in 2023 for patients with junctional or dystrophic EB.
Opening excerpt (first ~120 words) tap to expand
Denver — Thanks to treatments approved by the FDA in recent years, pediatric dermatologists’ strategy for epidermolysis bullosa (EB) has shifted from providing supportive care to correcting underlying causes and boosting wound healing, Emily Gorrell, DO, said at the annual Society for Pediatric Dermatology Pre-AAD meeting.Before 2022, she said, management of EB’s cutaneous manifestations was limited to managing pain and itching, preventing and treating infections, supporting wound healing, and watching for squamous cell carcinomas, which are often aggressive in the context of EB.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
